ArticleJournal of hepatocellular carcinoma2026
Identification of a Calcium-Related Prognostic Signature and Validation of CACNA1B as a Driver of Metastasis in Hepatocellular Carcinoma.
Article in Journal of hepatocellular carcinoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Hepatocellular carcinoma (HCC) is a significant global health burden. Cancer cells often exhibit an imbalance in intracellular calcium homeostasis. This study aims to explore the relationship between calcium-related genes and the prognosis of HCC, and establish a prognostic model based on calcium-related genes. Methods: This study comprehensively reviewed 392 calcium-related regulators and constructed a Calcium-related Prognostic Risk Score(CPRS) for HCC by means of bootstrap-based univariate Cox, random forest screening, and LASSO analysis. We developed an effective prognostic nomogram for patients with HCC by integrating the CPRS and clinicopathological features. The signature was developed using the TCGA cohort and validated in two independent external cohorts (ICGC and NODE-CHCC). Subsequently, we identified the key genes in CPRS that affect the prognosis of HCC based on SurvSHAP, and further investigated the impact of the key factor CACNA1B on the biological behavior of HCC cells. Results: CPRS was established with 6 calcium-related genes (CSN1S1, S100A9, CACNA1B, FKBP1A, SLC25A24 and SPP1). Our study showed that high CPRS is closely associated with higher histological grade, advanced TNM stage, vascular invasion, poorer progression-free and overall survival (OS) status of HCC, and CPRS can serve as an independent risk factor for the prognosis of HCC patients. The nomogram combining CPRS with TNM stage and patient age significantly improved the accuracy of predicting survival outcomes in HCC patients. Functional experiments revealed that inhibiting CACNA1B expression significantly suppressed cell proliferation, migration, and epithelial-mesenchymal transition signaling in HCC cells. Conclusion: We developed a novel CPRS that can accurately predict the prognosis of HCC. CACNA1B may function as a tumor promotor in HCC progression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.